

# Index

## A

- Abdominal closure, 164
- Adenocarcinoma in situ (AIS)
  - hysterectomy, 284
  - preinvasive lesions, 283
- AIS. *See* Adenocarcinoma in situ (AIS)
- Anorexia, 379
- Anti-angiogenic agents
  - AMG386, 211
  - ATEs, 207, 209–210
  - bevacizumab
    - AURELIA study, 206–207
    - GOG study 218, 202
    - OCEANS study, 206
  - BIBF1120 (nintedanib), 208, 211
  - cabozantinib (XL184), 208
  - efficacy, aflibercept *vs.* placebo, 207
  - GOG 252, 206
  - ICON7, 205
  - overexpression, VEGF, 202
  - sunitinib, 208
  - tyrosine kinase inhibitors (TKIs), 208
  - vandetanib, 211
- Antiangiogenic therapy, 235–236
- Arterial thromboembolic events (ATEs), 207, 209–210
- ATEs. *See* Arterial thromboembolic events (ATEs)
- Aurora kinase inhibitors, 218

## B

- Bevacizumab
  - AURELIA study, 206–207
  - GOG study 218, 202

- OCEANS study, 206
- BIBF1120 (nintedanib), 208, 211
- Bowel obstruction, 369, 370
- Bowel resection, 163

## C

- Cabozantinib (XL184), 208
- Calculation, CrCL formulae, 90
- Carboplatin
  - dosing
    - AURELIA study results, 240
    - calculation by GFR, 238
    - Calvert formula, 239
    - Cockcroft-Gault formula, 239
    - maximum allowed doses, 239
  - lower dose-intensity, 234
  - platelet toxicity, 234
- CARG and CRASH tools, 75–76
- Cervical cancer
  - clinical staging, 282
  - comorbidities, 12, 13
  - description, 278, 296, 354
  - diagnostic procedures, 279–280
  - FIGO staging, 278–279
  - HPV, 355
  - incidence and mortality
    - country-specific incidence and mortality rates in 2008, 3, 8
    - median age, 2
    - trend in age-standardized, 2, 5
  - locally advanced cervical cancer chemoradiation, 297–298
  - definition, 296
  - experimental therapies, 299
  - radiation therapy, 296–297

- Cervical cancer (*cont.*)
- metastatic and recurrent (*see* Metastatic and recurrent cervical cancer)
  - neovaginal reconstruction, 356
  - pelvic exenteration, 355–356
  - preinvasive lesions, 283
  - radiation therapy, 355
  - radiologic evaluation, 281–282
  - risk and protective factors, 10–11
  - surgery (*see* Surgical management)
  - surgical treatment, 355
  - survival, 12, 14–15, 16–17
  - vaginal toxicity and sexual dysfunction, 355
- Cervical carcinoma
- adenocarcinoma in situ (AIS), 31
  - CIN, 30
  - gene *p16INK4a*, 30
  - invasive squamous cell carcinoma (SCC), 30
- Cervical intraepithelial neoplasia (CIN)
- cryotherapy, 283
  - preinvasive lesions, 283
- CGA. *See* Comprehensive geriatric assessment (CGA)
- Chemotherapy
- carboplatin, 91
  - chemotherapeutic agents used, 90–91
  - comorbidity and polypharmacy, 84
  - docetaxel, 92
  - doxorubicin and PLD, 92–93
  - elderly patients, 83
  - gemcitabine, 93–94
  - measurement of renal function, 89
  - ovarian cancer (OC), 44–47
  - paclitaxel, 91–92
  - physiologic changes with aging, 85–87
  - PK (*see* Pharmacokinetics (PK))
  - postoperative adjuvant treatment options, 263–264
  - regimens in advanced and recurrent endometrial cancer
    - G-CSF, 266
    - GOG 107 study, 264, 266
    - randomized phase III trials, 264, 265
    - TAP regimen, 267
    - toxicity data, 266
  - second-line setting, 267–268
  - topotecan, 93
- CIN. *See* Cervical intraepithelial neoplasia (CIN)
- Cisplatin-based intraperitoneal (IP) chemotherapy, 177–178
- Clear cell carcinoma, 24
- Cognitive impairments, CGA, 68
- Comorbidities
- and polypharmacy, 84
  - cervical cancer, 12, 13
  - CGA, 66–67
  - ovarian cancer, 12, 13
  - uterine cancer, 12, 13
  - vulvar cancer, 12, 13
- Comprehensive geriatric assessment (CGA)
- advanced age, 63
  - comparison, selected screening tools, 78
  - components
    - cognition, 68
    - comorbidity, 66–67
    - functional status, 65–66
    - nutrition, 68–69
    - polypharmacy, 67
    - social support, 69
  - epidemiology
    - endometrial cancer, 64
    - ovarian cancer, 65
  - risk stratification, 69–71
  - screening for impairments
    - CARG and CRASH tools, 75–76
    - G8, 75
    - GFI, 74–75
    - measures, 71
    - PACE tool, 77
    - VES-13, 72–74
- CrCl. *See* Creatinine clearance (CrCl)
- Creatinine clearance (CrCl), 90
- CRS. *See* Cytoreductive surgery (CRS)
- Cytoreductive surgery (CRS)
- diagnosis and management
    - cardiopulmonary, 166
    - gastrointestinal, 167–168
    - hematologic, 166–167
    - infectious, 167
    - neuropsychiatric, 168
  - eligibility criteria, 152
  - impact of age
    - clinical outcomes, 153
    - multi-institutional review, 154
    - overall survival, 154
    - perioperative death, 153
    - population-based study, 153
    - retrospective analysis, 154–155
  - optimal primary CRS, 152
  - ovarian cancer (OC)
    - risk stratification, 42
    - series studies, 43
    - single institution case series, 43, 44

- postoperative issues in elderly patient, 165
- selection, surgical candidate
  - high-risk group of patients, 155
  - neoadjuvant chemotherapy, 155
  - surgical candidacy and resectability, 156

**D**

- Data sources used, epidemiology of
  - gynecological cancer, 18
- DESKTOP III trial, 195
- Diaphragm, 160–161
- Differentiated or simplex VIN (dVIN), 31–32
- Distal pancreatectomy, 162
- Docetaxel, 92
- Doxorubicin, 92
- Drug treatment, issues in
  - changes in pharmacokinetics
    - absorption, 230
    - distribution, 230
    - excretion, 231
    - metabolism, 230
  - medical comorbidities, 231
  - polypharmacy, 231
- dVIN. *See* Differentiated or simplex VIN (dVIN)

**E**

- Eindhoven Cancer Registry (ECR), 18
- End-of-life care
  - anorexia, 379
  - anxiety and depression, 379–381
  - ascites, 373–374
  - caregiver burden, 385
  - caution, 371
  - chemotherapeutic treatment, 369
  - cytotoxic treatments, 385
  - existential and spiritual distress, 384–385
  - fatigue, 378–379
  - fistulas, 372–373
  - functional assessment, 369
  - gastrointestinal hormones, 370
  - gastrostomy tube, 371
  - haloperidol, 370
  - lansoprazole, 370
  - nutrition and hydration, 371–372
  - octreotide, 370
  - ondansetron, 370
  - pain management
    - adjuvant agents, 376
    - benzodiazepines and pruritus, 376
    - cervical cancer, 377–378

- myoclonus, 376
- non-opioid analgesics, 375
- non-pharmacologic treatment, 376
- opioids, 375
- STOPP, 375
- transmucosal and transdermal
  - fentanyl, 375–376
  - visual analog/verbal rating scale, 374
- palliative and hospice care, 383–384
- palliative surgery, 370
- pathophysiologic effects, 386
- physician-patient communication, 381–382
- planning, 382–383
- promethazine, 370
- QOL, patients, 368
- symptom management, 368
- Endometrial cancer
  - advanced stage in elderly women
    - chemotherapy options, second-line setting, 267–268
  - chemotherapy regimens, 264–267
  - epidemiology, 257–261
  - hormonal treatment options, 268–270
  - novel pathways and targeted therapies, 270–272
  - postoperative adjuvant treatment options, 262–264
  - radiation as definitive treatment, 261–262
  - sexuality, 353–354
- Endometrial carcinoma
  - adenocarcinoma, 22
  - clear cell carcinoma, 24
  - FIGO grading scheme, 22
  - hyperplasia, 22
  - landular *vs.* solid architecture, 22
  - LS, 25–26
  - metaplasias, 23
  - MMMTs, 25
  - myometrial invasion, 23
  - serous carcinoma, 23–24
  - tamoxifen, 25
  - type II carcinomas, 21
  - undifferentiated carcinoma, 24
- Endometrial stromal nodule (ESN), 334
- Endometrial stromal sarcomas (ESSs)
  - adjuvant systemic therapy, 336
  - cellular atypia and mitotic rate, 334, 335
  - description, 333–334
  - ESNs, 334

- Endometrial stromal sarcomas (ESSs) (*cont.*)  
 estrogen antagonism, 338  
 FIGO staging system, 324, 334  
 hormonal therapy, 336–337  
 immunohistochemistry and molecular biology, 334, 335  
 metastatic treatment, 337  
 prognostic factors, 337–338  
 radiation treatment, 336  
 surgical treatment, 336  
 treatment, 335–336
- EOC. *See* Epithelial ovarian cancer (EOC)
- Epidemiology, endometrial cancer  
 distribution of stage by age, 257–258  
 multimodal adjuvant therapy, 261  
 relative survival time by age, 259–260  
 treatment options, 261
- Epidermal growth factor receptor (EGFR)  
 inhibitors, 212, 213
- Epithelial ovarian cancer (EOC)  
 intraoperative management  
 abdominal closure, 164  
 bowel resection, 163  
 cytoreduction, 159  
 diaphragm, 160–161  
 distal pancreatectomy, 162  
 intraperitoneal catheter placement, 164  
 liver mobilization, 160  
 liver resection, 161  
 lymphadenectomy, 163–164  
 omentectomy, 159  
 pelvis, 162–163  
 splenectomy, 161  
 staging, 158–159  
 upper abdomen, 159  
 preoperative assessment and preparation  
 consultation with anesthesiology, 157  
 PACE instrument, 157  
 serum tumor markers, 156–157
- ESN. *See* Endometrial stromal nodule (ESN)
- Eurocare, 18
- F**
- Familial linkage, 107–108
- Female Sexual Function Index (FSFI), 351, 359
- FIGO. *See* International Federation of Gynecology and Obstetrics (FIGO)
- First-line chemotherapy  
 gynecologic malignancies, 174  
 older cohort, 174  
 poor prognosis, 172
- RECIST response rate, 173
- SEER review, 172–173
- single-agent carboplatin, 173
- superior chemotherapy regimen, 172
- Folate receptor (FR) inhibitors, 214–215
- FSFI. *See* Female Sexual Function Index (FSFI)
- Functional status, CGA, 65–66
- G**
- G-CSF. *See* Granulocyte-colony stimulating factor (G-CSF)
- Genetic testing  
 BRCAPRO, 115  
 MMR proteins, 116  
 MMRpro for HNPCC risk, 115  
 recommendations, 114  
 SGO guidelines  
 BRCA, 115  
 HNPCC, 115  
 Tyrer-Cuzick Model (IBIS), 115  
 variants of uncertain significance (VUS), 116
- Geriatric Depression Scale (GDS), 102
- Geriatric issues in ovarian cancer  
 ACOVE VES-13, 49  
 delirium guidelines, 52  
 functional status, 48  
 individual interventions, 48  
 KPS or ECOG scores, 49  
 limited homeostatic reserve, 50  
 long-term care facility (LTCF), 52  
 NCCN Clinical Practice Guidelines, 50  
 post hoc subgroup analysis, 54  
 pre-cancer life expectancy, 51  
 precipitous discharges, 54  
 primary frailty and terminal disease, 48  
 risk factors, 53  
 staging the aging, 51
- GFI. *See* Groningen Frailty Indicator (GFI)
- GFR. *See* Glomerular filtration rate (GFR)
- GLOBOCAN, 18
- Glomerular filtration rate (GFR), 89
- GnRH. *See* Gonadotropin-releasing hormone (GnRH)
- GOG. *See* Gynecologic Oncology Group (GOG)
- GOG 213 study, 195
- Gonadotropin-releasing hormone (GnRH), 337
- Granulocyte-colony stimulating factor (G-CSF), 266
- Groningen Frailty Index, 101–102

- Groningen Frailty Indicator (GFI), 74–75
- Gynecologic cancers
- cervical, 354–356
  - chronic medical conditions, 357
  - diagnosis and treatment, 360
  - end-of-life care (*see* End-of-life care)
  - endometrial, 353–354
  - epidemiology, 350–351
  - female sexual dysfunction, 350
  - FSFI, 351
  - ovarian, 352–353
  - pelvic floor, 351
  - physician-patient communication process, 351
  - psychosocial factors, 356–357
  - sexual function, 359
  - stereotypes and stigma, 350
  - vaginal health promotion strategies and solutions
    - dilator therapy, 358
    - estrogen replacement, 358
    - hormones, 357, 358
    - moisturizers and lubricants, 357–358
    - nonhormonal treatments, 357
    - vulvar and vaginal, 354
- Gynecologic malignancies
- prevention, 117
  - screening strategies
    - endometrial cancer, 116
    - ovarian cancer, 116
- Gynecologic Oncology Group (GOG), 316
- Gynecological cancer survivors, 12, 14
- H**
- HBOC. *See* Hereditary breast and ovarian cancers (HBOC)
- Hedgehog (Hh) pathway inhibitors, 214
- Hereditary breast and ovarian cancers (HBOC)
- BRCA
    - genetic function, 109
    - specific mutations, 109–110
    - clinical aspects, 108–109
    - fallopian tube malignancies, 110–111
- Hereditary nonpolyposis colorectal cancer (HNPCC)
- clinical aspects, 111–112
  - DNA MMR genetic function, 113
  - endometrial cancer, 112
  - ovarian cancer, 112–113
  - specific mutations, 113–114
- HGSC. *See* High-grade serous carcinoma (HGSC)
- High-grade serous carcinoma (HGSC), 27, 28
- HNPCC. *See* Hereditary nonpolyposis colorectal cancer (HNPCC)
- Hormonal treatment options
- cochrane database review, 269
  - progesterin therapy, 268
  - tamoxifen, 269
- Hormone therapy, 236–237
- HPV. *See* Human papillomavirus (HPV)
- Human papillomavirus (HPV), 355
- I**
- Incidence and mortality
- cervical cancer, 2–3, 5, 8
  - ovarian cancer, 2–3, 8
  - uterine cancer, 1–2, 3, 8
  - vulvar cancer, 4, 9
- Inherited disorders, 114
- International Federation of Gynecology and Obstetrics (FIGO)
- carcinoma, 279
  - microinvasion, 278
  - staging system, 278
- Intraperitoneal catheter placement, 164
- Intraperitoneal chemotherapy, 177–178
- L**
- Large bowel obstruction (LBO), 395–396
- LBO. *See* Large bowel obstruction (LBO)
- LEEP. *See* Loop electrosurgical excision procedure (LEEP)
- Leiomyosarcoma (LMS)
- adjuvant radiotherapy, 325, 326
  - chemotherapy, 326–327
  - description, 321–322
  - hormonal therapy, 328–329
  - immunohistochemistry and molecular biology, 322
  - metastatic disease, 327–328
  - ovarian conservation, 325
  - pathological features, 322, 323
  - prognosis, 325, 326
  - staging and primary surgical treatment, 324–325
  - temozolomide, 329
  - trabectedin, 329
- LGSC. *See* Low-grade serous carcinoma (LGSC)
- Liver mobilization, 160
- LMS. *See* Leiomyosarcoma (LMS)

- Loop electrosurgical excision procedure (LEEP), 283
- Low-grade serous carcinoma (LGSC), 27, 28
- LS. *See* Lynch Syndrome (LS)
- Lymphadenectomy, 163–164
- Lynch Syndrome (LS)
- development, gynecologic malignancies, 26
  - DNA mismatch repair proteins, 25
  - pathologic features, 26
- M**
- Malignant bowel obstruction (MBO), 393
- Malignant mixed Mullerian tumors (MMMTs)
- adjuvant therapy
    - chemotherapy, 332
    - radiation therapy, 332
  - carboplatin and paclitaxel, 333
  - description, 329
  - immunohistochemistry, 331
  - metastatic treatment, 333
  - non-contraceptive estrogens, 330
  - obesity, 330
  - pathological features, 330
  - staging, 331
  - surgical treatment, 331
- Management, ovarian cancer
- chemotherapy treatments, 233–234
  - neoadjuvant treatment, 232–233
  - SEER data, 231–232
  - surgical treatment, 232
- MBO. *See* Malignant bowel obstruction (MBO)
- Metastatic and recurrent cervical cancer
- chemotherapy, elderly population, 300–301
  - experimental treatments, 302
  - lymph nodes, 299–300
  - platinum-based chemotherapeutic agent, 301
  - toxicity profile, 301–302
- Metastatic disease, 397
- MMMTs. *See* Malignant mixed Mullerian tumors (MMMTs)
- Morbidity associated with secondary cytoreductive surgery, 191–192
- Mucinous carcinoma, 29
- N**
- NACT. *See* Neoadjuvant chemotherapy (NACT)
- Neoadjuvant chemotherapy (NACT), 175–176
- Nonsteroidal anti-inflammatory (NSAIDs), 375
- NORDCAN, 18
- Novel pathways and targeted therapies
- anti-angiogenic therapies, 271
  - ATHENA study, 271
  - EGFR expression, 270
  - grade 3–4 adverse effects, 271
  - median age, 270
  - ongoing trials, 272
  - PIK3CA mutations, 270
  - tyrosine kinase inhibitors (TKIs), 272
- NSAIDs. *See* Nonsteroidal anti-inflammatory (NSAIDs)
- Nutrition, CGA, 68–69
- O**
- OCCC. *See* Ovarian clear cell carcinoma (OCCC)
- OEC. *See* Ovarian endometrioid carcinoma (OEC)
- Olaparib
- BRCA1 or BRCA2 mutation, 215
  - description, 215
  - phase I study, 218
  - randomized trials, 216–217
- Omentectomy, 159
- OSC. *See* Ovarian serous carcinoma (OSC)
- Ovarian cancer (OC)
- age groups, 46
  - age-related considerations for targeted therapies
    - pharmacokinetic variability, 201
    - selected therapies of interest, 201
  - chemotherapy
    - age groups, 46
    - dosing, 46
    - intraperitoneal therapy (IP), 45
    - OVAR-3 Phase III trial, 45
    - overall survival, 44–45
    - SEER-Medicare data set, 45
    - standard geriatric measures, 45
  - comorbidities, 12, 13
  - cytoreductive surgery
    - risk stratification, 42
    - series studies, 43
    - single institution case series, 43, 44
  - diagnosis, 40
  - disparities, 56–57
  - dosing, 46
  - elderly patients with, 200
  - factors associated with clinician delay, diagnosis, 141

- first-line chemotherapy, 172–174
- five most common sites, mortality, 41
- geriatrics (*see* Geriatric issues in ovarian cancer)
- incidence and mortality
  - by age, 2, 3
  - country-specific incidence and mortality rates in 2008, 2, 8
- incidence rates, 40
- intraoperative chemotherapy, 177–178
- intraperitoneal therapy (IP), 45
- median age at diagnosis, 40, 41
- mortality, 40
- NACT, 175–176
- NCCN Clinical Practice Guidelines, 42
- OVAR-3 Phase III trial, 45
- overall survival, 44–45
- population ages and life expectancy, 171
- restaging the aging, 54–55
- risk and protective factors, 10
- SEER-Medicare data set, 45
- standard geriatric measures, 45
- standard of care, 41–42
- supportive management, 55–56
- survival, 12, 14–15, 16–17, 40
- survival disparity, 172
- symptoms (*see* Symptoms, ovarian cancer)
- targeted agents, 219
- targeted therapies under investigation
  - anti-angiogenic agents (*see* Anti-angiogenic agents)
  - aurora kinase inhibitors, 218
  - EGFR inhibitors, 212
  - FR inhibitors, 214–215
  - Hh pathway inhibitors, 214
  - immunotherapy, 218–219
  - PARP inhibitors, 215–218
  - PI3K-AKT-mTOR pathway inhibitors, 212–214
- Ovarian carcinoma
  - leiomyosarcoma, 30
  - mucinous carcinoma, 29
  - OCCC, 29
  - OEC, 28
  - OSC, 26–28
- Ovarian clear cell carcinoma (OCCC), 29
- Ovarian endometrioid carcinoma (OEC), 28
- Ovarian serous carcinoma (OSC)
  - BRCA* abnormalities, 27–28
  - categories, 26–27
  - description, 26
  - grading schemes, 27
  - occult carcinomas, 27
  - STIC, 27–28
- P**
- PACE tool, 77
- Paclitaxel, 91–92
- Palliative surgery
  - alleviate symptoms, 397
  - anesthetic care and cardiopulmonary resuscitation, 392
  - clinical medicine, 391
  - fistulas, 396
  - MBO, 393
  - medical management, 394
  - patient selection and prognostic factors, 394–395
  - pleural effusion, 397
  - principles, 392
  - procedures, 395–396
  - QOL factors, 393
  - urinary obstruction, 396–397
- Pathology, gynecologic cancer
  - cervical carcinoma, 30–31
  - endometrial carcinoma, 21–26
  - ovarian carcinoma, 26–30
  - vulvar carcinoma, 31–32
- PEComa. *See* Perivascular epithelioid cell tumor (PEComa)
- Pegylated liposomal doxorubicin (PLD), 92–93
- Perivascular epithelioid cell tumor (PEComa)
  - clinical behavior, 341
  - description, 341
  - pathology and immunohistochemistry, 342
  - treatment, 342
- PET. *See* Positron emission tomography (PET)
- Pharmacodynamics, 90
- Pharmacokinetics (PK)
  - absorption, 87–88
  - distribution, 88
  - drug metabolism and hepatic function, 88–89
  - excretion and renal function, 89
- Physiological and Operative Severity Score for enUmeration of Mortality and morbidity (POSSUM), 101
- PI3K-AKT-mTOR pathway inhibitors, 212–214
- PK. *See* Pharmacokinetics (PK)
- Platinum chemotherapeutic agents, 299, 301
- Platinum-sensitive recurrent disease
  - CALYPSO study, 234
  - ICON4 results, 234

Platinum-sensitive recurrent disease (*cont.*)

PLD-containing doublet, 234  
treatment

antiangiogenic therapy,  
235–236

chemotherapy, 235

hormone therapy, 236–237

PLD. *See* Pegylated liposomal doxorubicin (PLD)

Poly (ADP-ribose) polymerase (PARP)  
inhibitors

BER pathway, 215

olaparib

BRCA1 or BRCA2 mutation, 215

description, 215

phase I study, 218

randomized trials,

216–217

Polypharmacy, CGA, 67

Positron emission tomography (PET),  
314

Postoperative adjuvant treatment options

chemotherapy

GOG trial (GOG 122), 263

hematologic growth factor,  
264

TAP regimen, 264

vaginal brachytherapy, 264

radiotherapy

overall survival and disease-specific  
survival, 263

PORTEC-2 trial, 262–263

radiation tolerance, 262

WAI, 262

Preoperative risk assessment

comorbidity, 100

malnourishment, 102

P-POSSUM, 101

patients' perspectives and targets,  
103

physical fitness and outcome,  
102

prehabilitation, 102

relationship, advanced age and comorbid  
conditions, 100

retrospective series, 101

surgical excision, 100

**Q**

QOL. *See* Quality of life (QOL)

Quality of life (QOL),

368, 369, 385, 386

**R**

Radiation, non-operable endometrial cancer  
patients

hysterectomy, 261

overall survival, 262

physician choices and patient  
decisions, 262

Radical hysterectomy, 284, 285

Radiotherapy

cervical cancer

concurrent chemo-radiation therapy  
(CCRT), 130

DFS and specific survival rates  
(SSR), 129

high incidence, late adverse effect, 129

intensive monitoring, 130

radical radiotherapy (RT), 128

Surveillance Epidemiology and End  
Results records (SEER), 128

endometrial cancer

external beam radiotherapy (EBRT),  
124

GOG-99, 125

impact of age, 126–128

pelvic RT, 126

PORTEC-1 trial, 125

PORTEC-2 trial, 125

PORTEC-3 trial, 126

treatment-related toxicity, 134

vaginal cancer

EBRT, 133

high-dose-rate (HDR) brachytherapy,  
133

incidence, complication rates, 134

length of vaginal wall involvement, 132

proximity of vagina, 133

vulvar cancer

multifactorial analysis, 130–131

NCI treatment options, 131

SEER database, 131

sentinel node detection, 132

Receiver operating curves (ROC), 143–144

Recurrent epithelial ovarian cancer. *See*

Secondary cytoreductive surgery

Recurrent ovarian cancer

management (*see* Management, ovarian  
cancer)

patient communication, 237

Relapse. *See* Secondary cytoreductive surgery

Rhabdomyosarcoma

description, 340

pathology and immunohistochemistry, 340

treatment, 341



- Risk and protective factors  
 cervical cancer, 10–11  
 ovarian cancer, 10  
 uterine cancer  
   breast cancer, 7  
   Lynch syndrome, 8  
   oral contraceptives (OC) use, 9  
   type I endometrial carcinoma, 5, 7  
   type II endometrial carcinoma, 9–10  
 vulvar cancer, 11
- ROC. *See* Receiver operating curves (ROC)
- S**
- SBO. *See* Small bowel obstruction (SBO)
- Screening strategies, gynecologic malignancies  
 endometrial cancer, 116  
 ovarian cancer, 116
- Screening tool of older persons potentially inappropriate prescriptions (STOPP), 375
- Secondary cytoreduction. *See* Secondary cytoreductive surgery
- Secondary cytoreductive surgery  
 DESKTOP III trial, 195  
 goal, 184  
 GOG 213 study, 195  
 in elderly, 193–194  
 morbidity associated with, 191–192  
 surgical approach, 194–195  
 surveillance practices, 185–186  
 survival benefit associated with, 186–188  
 terminology, 184–185  
 variables predictive  
   overall prognosis, 188–189  
   surgical outcome, 189–191
- Selection criteria, secondary cytoreduction  
 overall prognosis, 188–189  
 surgical outcome, 189–191
- Selective serotonin reuptake inhibitors (SSRI), 380
- Serotonin-norepinephrine reuptake inhibitors (SNRI), 380
- Serous carcinoma  
 description, 23  
 myometrial invasion, 23–24  
*Tp53*, 24
- Serous tubal intraepithelial carcinoma (STIC), 27–28
- Sexual medicine, older patients. *See* Gynecologic cancers
- Small bowel obstruction (SBO), 395
- SNRI. *See* Serotonin-norepinephrine reuptake inhibitors (SNRI)
- Social support, CGA, 69
- Splenectomy, 161
- SSRI. *See* Selective serotonin reuptake inhibitors (SSRI)
- Stages, endometrial cancer  
 advanced  
   local-regional spread of disease, 249–250  
   stage IV disease, 250–251  
 early  
   adjuvant therapy *vs.* none, 247–249  
   surgery *vs.* no surgery, 245–246  
   surgical staging *vs.* no staging, 246–247
- STIC. *See* Serous tubal intraepithelial carcinoma (STIC)
- STOPP. *See* Screening tool of older persons potentially inappropriate prescriptions (STOPP)
- Sunitinib, 208
- Surgical management  
 colostomy, 288  
 complications, 286  
 FIGO clinical stage, 286, 287  
 intraoperative complications, 288  
 lymph nodes, 288  
 metastatic disease, 287  
 patient age, 290  
 pelvic exenteration, 286–287  
 population-based study, 290  
 preinvasive lesions treatment, 283  
 procedures, 283–285  
 radical trachelectomy, 289  
 robotic approach, 286  
 vagina, 289
- Surveillance practices, recurrent ovarian cancer  
 CA 125, 185  
 CT sensitivity and specificity, 185–186  
 magnetic resonance imaging (MRI), 186  
 PET/CT, 186
- Survival  
 cervical cancer, 12, 14–15, 16–17  
 ovarian cancer, 12, 14–15, 16–17  
 uterine cancer, 12, 14–15, 16–17  
 vulvar cancer, 12, 14–15, 16–17
- Survival benefit associated with secondary cytoreductive surgery  
 DESKTOP OVAR, 187–188  
 increasing tumor resection, 188  
 overall survival, 187

Symptom Index Questionnaire, 146  
 Symptoms, ovarian cancer  
   abdominal and pelvic symptoms, 142  
   cancer cases vs. controls, 142  
   cost-effective screening test, 145  
   evaluation by stage, 140  
   follow up case control study, 143  
   frequency of, 140  
   physician-and patient-related delays, 141  
   population-based screening, 147  
   receiver operating curves (ROC),  
     143–144  
   retrospective studies, 140  
   steps to diagnosing, 147  
   symptom index, 144  
   timely diagnosis, 147

## T

Tamoxifen, 25  
 The Society of Gynecologic Oncologists  
   (SGO) guidelines  
     BRCA, 115  
     HNPPC, 115  
 Topotecan, 93  
 Treatment, endometrial cancer  
   advanced stage  
     local-regional spread of disease,  
       249–250  
     stage IV disease, 250–251  
   clinically early stage  
     adjuvant therapy vs. none, 247–249  
     surgery vs. no surgery, 245–246  
     surgical staging vs. no staging,  
       246–247  
   description, 244  
   elderly population in US, 243  
   factors on mortality, 244  
   Wright analysis, 244

## U

UESs. *See* Undifferentiated endometrial  
 sarcomas (UESs)  
 Undifferentiated carcinoma, 24  
 Undifferentiated endometrial sarcomas  
   (UESs)  
     IGF1R and kinase inhibitors, 339  
     immunohistochemistry, 338  
     molecular biology, 339  
     pathological features, 338  
     treatment, 339  
 Urinary obstruction, 396–397  
 Usual VIN (uVIN), 31

Uterine cancer  
   comorbidities, 12, 13  
   incidence and mortality  
     by age, 2, 3  
     country-specific incidence and  
       mortality rates in 2008, 2, 8  
   description, 1  
   risk and protective factors  
     breast cancer, 7  
     Lynch syndrome, 8  
     oral contraceptives (OC) use, 9  
     type I endometrial carcinoma, 5, 7  
     type II endometrial carcinoma, 9–10  
   survival, 12, 14–15, 16–17  
 Uterine sarcomas  
   classification, 320–321  
   clinical trial data, 343  
   ESS (*see* Endometrial stromal sarcomas  
     (ESSs))  
   LMS (*see* Leiomyosarcoma (LMS))  
   malignant mixed Müllerian tumors,  
     329–333  
   mesenchymal elements, 319  
   PEComas, 341–342  
   pelvic irradiation, 321  
   rhabdomyosarcoma, 340–341  
   UESs (*see* Undifferentiated endometrial  
     sarcomas (UESs))  
 uVIN. *See* Usual VIN (uVIN)

## V

Vaginal cancer  
   chemotherapeutic agent, 316  
   diagnosis and treatment, 314–315  
   epidemiology, 313–314  
   metastatic disease, 314  
   palliative chemotherapy, 316  
   treatment effect, 315  
 Vaginal health  
   dilator therapy, 358  
   estrogen replacement, 358  
   hormonal therapy, 359  
   moisturizers and lubricants, 357–358  
   nonhormonal strategies, 357  
 Vandetanib, 211  
 Variants of uncertain significance (VUS),  
   116  
 VES-13. *See* Vulnerable Elders Survey-13  
   (VES-13)  
 VIN. *See* Vulvar intraepithelial neoplasia  
   (VIN)  
 Vulnerable Elders Survey-13  
   (VES-13), 72–74, 102

## Vulvar cancer

- Bartholin gland, 309
- chemoradiation therapy, 311–312
- comorbidities, 12, 13
- diagnosis, 309
- epidemiology, 307–308
- incidence and mortality
  - age-adjusted incidence, 4
  - trend in age-standardized, 4, 9
- melanoma, 309
- prognostic factors, 310
- radiation therapy, 312–313
- risk and protective factors, 11
- squamous cell carcinoma, 308
- surgical management, 310–311

- survival, 12, 14–15, 16–17
- symptoms and lesions, 313

## Vulvar carcinoma

- dVIN, 31–32
- HPV-associated VIN, 31
- uVIN, 31

## Vulvar intraepithelial neoplasia (VIN), 31–32

VUS. *See* Variants of uncertain significance (VUS)**W**

- WAI. *See* Whole abdominal irradiation (WAI)
- Whole abdominal irradiation (WAI), 262, 263